{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:41:09Z","timestamp":1782794469554,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Identification of immunogenic targets against hepatitis B virus (HBV)-encoded proteins will provide crucial advances in developing potential antibody therapies. In this study, 63 treatment-na\u00efve patients with chronic HBV infection and 46 patients who achieved hepatitis B surface antigen loss (sAg loss) following antiviral treatment were recruited. Moreover, six patients who transitioned from the hepatitis B e antigen-positive chronic infection phase (eAg<jats:sup>+<\/jats:sup>CInf) to the hepatitis phase (eAg<jats:sup>+<\/jats:sup>CHep) were enrolled from real-life clinical practice. Additionally, telbivudine-treated eAg<jats:sup>+<\/jats:sup>CHep patients and relapsers or responders from an off-treatment cohort were longitudinally studied. The frequencies and function of B cells were assessed by flow cytometry. We devised a peptide array composed of 15-mer overlapping peptides of HBV-encoded surface (S), core (C), and polymerase (P) proteins and performed a screening on B-cell linear epitopes with sera. Na\u00efve B cells and plasmablasts were increased, whereas total memory, activated memory (AM), and atypical memory (AtM) B cells were reduced in sAg<jats:sup>-<\/jats:sup> patients compared with sAg<jats:sup>+<\/jats:sup> patients. Importantly, longitudinal observations found that AtM B cells were associated with successful treatment withdrawal. Interestingly, we identified six S-specific dominant epitopes (S33, S34, S45, S76, S78, and S89) and one C-specific dominant epitope (C37) that reacted with the majority of sera from sAg<jats:sup>-<\/jats:sup> patients. Of note, more B-cell linear epitopes were detected in CHep patients with alanine aminotransferase (ALT) flares than in nonflare CInf patients, and five B-cell linear epitopes (S4, S5, S10, S11, and S68) were overwhelmingly recognized by ALT flare patients. The recognition rates of epitopes on C and P proteins were significantly increased in CHep patients relative to CInf patients. Strikingly, a statistically significant elevation in the number of positive epitopes was observed when ALT nonflare patients shifted into the flare phase. Moreover, S76 identified at baseline was confirmed to be associated with a complete response after 48 weeks of telbivudine therapy. Taken together, we identified several functional cure-related B-cell linear epitopes of chronic HBV infection, and these epitopes may serve as vaccine candidates to elicit neutralizing antibodies to treat HBV infection.<\/jats:p>","DOI":"10.3389\/fimmu.2021.767000","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T03:35:38Z","timestamp":1634355338000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array"],"prefix":"10.3389","volume":"12","author":[{"given":"Shuqin","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s2468-1253(18)30056-6","article-title":"Global Prevalence, Treatment, and Prevention of Hepatitis B Virus Infection in 2016: A Modelling Study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic Strategies for Hepatitis B Virus Infection: Towards a Cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-239","article-title":"Medical Virology of Hepatitis B: How it Began and Where We are Now","volume":"10","author":"Gerlich","year":"2013","journal-title":"Virol J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(73)92004-7","article-title":"Antibody to Hepatitis-B-Virus Core in Man","volume":"2","author":"Hoofnagle","year":"1973","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003854107","article-title":"B Cell Gene Signature With Massive Intrahepatic Production of Antibodies to Hepatitis B Core Antigen in Hepatitis B Virus-Associated Acute Liver Failure","volume":"107","author":"Farci","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2020.1869391","article-title":"Preparation and Functional Evaluation of Monoclonal Antibodies Targeting Hepatitis B Virus Polymerase","volume":"12","author":"Hu","year":"2021","journal-title":"Virulence"},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e20200840","DOI":"10.1084\/jem.20200840","article-title":"Potent Human Broadly Neutralizing Antibodies to Hepatitis B Virus From Natural Controllers","volume":"217","author":"Hehle","year":"2020","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308964","article-title":"Prolonged Suppression of HBV in Mice by a Novel Antibody That Targets a Unique Epitope on Hepatitis B Surface Antigen","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317725","article-title":"A Unique B Cell Epitope-Based Particulate Vaccine Shows Effective Suppression of Hepatitis B Surface Antigen in Mice","volume":"69","author":"Zhang","year":"2020","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.chom.2020.05.010","article-title":"A Combination of Human Broadly Neutralizing Antibodies Against Hepatitis B Virus HBsAg With Distinct Epitopes Suppresses Escape Mutations","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.69","article-title":"Immune Responses and Immunopathology in Acute and Chronic Viral Hepatitis","volume":"16","author":"Shin","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of Hepatitis B Virus Persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41598-020-58870-2","article-title":"Circulating Serum HBsAg Level is a Biomarker for HBV-Specific T and B Cell Responses in Chronic Hepatitis B Patients","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg Seroclearance After Nucleoside Analogue Therapy in Patients With Chronic Hepatitis B: Clinical Outcomes and Durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg Seroclearance Further Reduces Hepatocellular Carcinoma Risk After Complete Viral Suppression With Nucleos(T)Ide Analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12876-020-01263-6","article-title":"HBsAg Quantification Predicts Off-Treatment Response to Interferon in Chronic Hepatitis B Patients: A Retrospective Study of 250 Cases","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.10.020","article-title":"High Serum IL-21 Levels After 12 Weeks of Antiviral Therapy Predict HBeAg Seroconversion in Chronic Hepatitis B","volume":"56","author":"Ma","year":"2012","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/srep13364","article-title":"Chimeric Peptide Constructs Comprising Linear B-Cell Epitopes: Application to the Serodiagnosis of Infectious Diseases","volume":"5","author":"Lu","year":"2015","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01573-19","article-title":"Epitope-Containing Short Peptides Capture Distinct IgG Serodynamics That Enable Differentiating Infected From Vaccinated Animals for Live-Attenuated Vaccines","volume":"94","author":"Xue","year":"2020","journal-title":"J Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1134409","article-title":"A Human Monoclonal Antibody Against Small Envelope Protein of Hepatitis B Virus With Potent Neutralization Effect","volume":"8","author":"Wang","year":"2015","journal-title":"mAbs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2018.06.001","article-title":"Genome-Wide Linear B-Cell Epitopes of Enterovirus 71 in a Hand, Foot and Mouth Disease (HFMD) Population","volume":"105","author":"Zhang","year":"2018","journal-title":"J Clin Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1815591","article-title":"Functional Mapping of B-Cell Linear Epitopes of SARS-CoV-2 in COVID-19 Convalescent Population","volume":"9","author":"Yi","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12072-019-09998-5","article-title":"Use of HBsAg Quantification in the Natural History and Treatment of Chronic Hepatitis B","volume":"14","author":"Mak","year":"2020","journal-title":"Hepatol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection","volume":"11","author":"Hoogeveen","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci121960","article-title":"Circulating and Intrahepatic Antiviral B Cells are Defective in Hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jhep.2019.07.015","article-title":"Comparative Characterization of B Cells Specific for HBV Nucleocapsid and Envelope Proteins in Patients With Chronic Hepatitis B","volume":"72","author":"Le Bert","year":"2020","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/jci121957","article-title":"PD-1 Blockade Partially Recovers Dysfunctional Virus-Specific B Cells in Chronic Hepatitis B Infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01680-20","article-title":"Identification of Two Critical Neutralizing Epitopes in the Receptor Binding Domain of Hepatitis B Virus Pres1","volume":"95","author":"Yato","year":"2020","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MA0620-023RR","article-title":"Identification of the Association Between HBcAg-Specific T Cell and Viral Control in Chronic HBV Infection Using a Cultured ELISPOT Assay","volume":"109","author":"Chen","year":"2021","journal-title":"J Leukoc Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02048","article-title":"HBV-Induced Immune Imbalance in the Development of HCC","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High Risk of Hepatocellular Carcinoma and Death in Patients With Immune-Tolerant-Phase Chronic Hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104816","article-title":"Mechanisms of HBV Immune Evasion","volume":"179","author":"Kuipery","year":"2020","journal-title":"Antiviral Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium Taurocholate Cotransporting Polypeptide is a Functional Receptor for Human Hepatitis B and D Virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive Immunity in HBV Infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.767000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T03:35:45Z","timestamp":1634355345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.767000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2021.767000"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.767000","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"article-number":"767000"}}